BCL2 and cancer: Additionally, the observed upregulation of pro-apoptotic genes such as BAX and Caspases in MCF-7, MDA-MB-231, T-47D, and U-937 cells, alongside minimal changes in BCL-2 in HSF cells, suggests that Brentuximab induces apoptosis preferentially in cancer cells while sparing normal fibroblasts.